Insiders · RGLS

RGLS insider transactions

Regulus Therapeutics Inc. (RGLS) Form 4 insider transactions - real-time wire coverage of every officer, director, and 10% owner trade.

RGLS insiders

Everyone who has filed a Form 3, 4, 5 or 144 at Regulus Therapeutics Inc., latest first. Follow anyone to get their next filing.

• Pascale WitzDirector
• William H RastetterDirector
• Stelios PapadopoulosDirector
• Hugh RosenDirector
• Preston KlassenPresident & Head of R & D, Director, since June 2023+$95.9K-$39.7K
• Christopher Ray AkerSr. VP & General Counsel-$63.8K
• Joseph P HaganChief Executive Officer, Director+$75.8K-$192K
• David BaltimoreDirector+$20.8K
• Jason Raleigh NunnDirector
• Alice Shih-hou HuangDirector, since January 2021
• Kathryn J CollierDirector+$7,280
• Crispina CalsadaChief Financial Officer-$61.8K
• Simos SimeonidisDirector
• Denis DryginOfficer+$23K
• Paul Edward WalkerInsider
• Peter W. SonsiniInsider
• Scott D SandellInsider
• Joshua MakowerInsider
• Mohamad MakhzoumiInsider
• Anthony A. Florence Jr.Insider
• Carmen ChangInsider
• Ali BehbahaniInsider
• Forest BaskettInsider
• Growth Equity Opportunities V, LLCInsider

Recent Form 3, 4, and 5 filings for RGLS

• 499d
  Director Rastetter William H returned 57,292 shares to the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  Director Witz Pascale returned 67,233 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  Director Papadopoulos Stelios returned 64,635 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  Director Rosen Hugh returned 57,292 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  President & Head of R & D Klassen Preston returned 115,555 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  Sr. VP & General Counsel Aker Christopher Ray returned 83,125 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  Chief Executive Officer Hagan Joseph P returned 571,558 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  Director Baltimore David returned 114,584 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  Director Nunn Jason Raleigh returned 62,500 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  Director Huang Alice Shih-Hou returned 114,584 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  Director Collier Kathryn J returned 75,565 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 499d
  Chief Financial Officer Calsada Crispina returned 140,228 shares to the company, closing all direct ownership in the company (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 508d
  Director Collier Kathryn J exercised 6,325 shares at a strike of $9.50, decreasing direct ownership by 5% to 62,915 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 522d
  President & Head of R & D Klassen Preston bought $95,852 worth of shares (12,000 units at $7.99), increasing direct ownership by 33% to 48,055 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 557d
  Director Nunn Jason Raleigh was granted 62,500 shares (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 557d
  Director Collier Kathryn J was granted 62,500 shares, increasing direct ownership by 927% to 69,240 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 557d
  Director Witz Pascale was granted 62,500 shares, increasing direct ownership by 1,321% to 67,233 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 557d
  Director Baltimore David was granted 125,000 shares, increasing direct ownership by 282% to 84,669 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 557d
  Director Papadopoulos Stelios was granted 62,500 shares, increasing direct ownership by 6% to 1,040,888 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 557d
  Director Rosen Hugh was granted 62,500 shares, increasing direct ownership by 3,529% to 64,271 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 557d
  Director Rastetter William H was granted 62,500 shares (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 557d
  Director Huang Alice Shih-Hou was granted 125,000 shares (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 646d
  SEC Form 4 filed by Sr. VP & General Counsel Aker Christopher Ray

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 646d
  SEC Form 4 filed by Chief Financial Officer Calsada Crispina

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 646d
  Chief Executive Officer Hagan Joseph P bought $54,260 worth of shares (50,000 units at $1.09), increasing direct ownership by 24% to 260,808 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 646d
  Director Baltimore David bought $20,787 worth of shares (19,610 units at $1.06), increasing direct ownership by 766% to 22,169 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 646d
  SEC Form 4 filed by President & Head of R & D Klassen Preston

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 662d
  Chief Financial Officer Calsada Crispina sold $55,333 worth of shares (43,804 units at $1.26), decreasing direct ownership by 49% to 45,478 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 662d
  Chief Executive Officer Hagan Joseph P sold $160,495 worth of shares (127,054 units at $1.26), decreasing direct ownership by 38% to 210,808 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 662d
  President & Head of R & D Klassen Preston sold $39,721 worth of shares (31,445 units at $1.26), decreasing direct ownership by 47% to 36,055 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 662d
  Sr. VP & General Counsel Aker Christopher Ray sold $55,120 worth of shares (43,635 units at $1.26), decreasing direct ownership by 47% to 49,546 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 667d
  Chief Financial Officer Calsada Crispina was granted 83,500 shares, increasing direct ownership by 1,444% to 89,282 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 667d
  Chief Executive Officer Hagan Joseph P was granted 280,750 shares, increasing direct ownership by 492% to 337,862 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 667d
  President & Head of R & D Klassen Preston was granted 67,500 shares (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 667d
  Sr. VP & General Counsel Aker Christopher Ray was granted 84,125 shares, increasing direct ownership by 929% to 93,181 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 832d
  Director Collier Kathryn J bought $7,280 worth of shares (4,000 units at $1.82), increasing direct ownership by 146% to 6,740 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Rastetter William H

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Papadopoulos Stelios

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Witz Pascale

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Rosen Hugh

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Nunn Jason Raleigh

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Collier Kathryn J

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Huang Alice Shih-Hou

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Baltimore David

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Klassen Preston

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Hagan Joseph P

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Calsada Crispina

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 901d
  SEC Form 4 filed by Aker Christopher Ray

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 905d
  SEC Form 4 filed by Collier Kathryn J

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 905d
  SEC Form 4 filed by Nunn Jason Raleigh

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 905d
  SEC Form 4 filed by Baltimore David

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 905d
  SEC Form 4 filed by Rosen Hugh

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 905d
  SEC Form 4 filed by Witz Pascale

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 905d
  SEC Form 4 filed by Papadopoulos Stelios

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 905d
  SEC Form 4 filed by Rastetter William H

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 905d
  SEC Form 4 filed by Huang Alice Shih-Hou

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 968d
  Papadopoulos Stelios was granted 250,000 shares, increasing direct ownership by 34% to 978,388 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 1025d
  Calsada Crispina sold $6,510 worth of shares (5,468 units at $1.19), decreasing direct ownership by 49% to 5,782 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 1025d
  Aker Christopher Ray sold $6,510 worth of shares (5,468 units at $1.19), decreasing direct ownership by 35% to 10,056 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)
• 1025d
  Hagan Joseph P sold $17,359 worth of shares (14,580 units at $1.19), decreasing direct ownership by 20% to 57,112 units (SEC Form 4)

  4 - Regulus Therapeutics Inc. (0001505512) (Issuer)